Polymyositis Market Analysis Reflecting Expansion Trends And Industry Performance

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Forecasted Rise In Market Size Of The Polymyositis Market During The Forecast Period?

The polymyositis market size has experienced robust growth in recent years. It is projected to expand from $1.74 billion in 2025 to $1.85 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.2%. This historical growth can be attributed to several factors including an improved understanding of autoimmune myopathies, the availability of muscle biopsy diagnostics, increased use of corticosteroids, the expansion of hospital diagnostic capabilities, and the rising identification of rare muscle disorders.

The polymyositis market is projected to experience substantial expansion in the coming years. This market is anticipated to reach a valuation of $2.34 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.0%. Key drivers for this growth during the forecast period include the increasing development of targeted immune therapies, greater integration of precision diagnostics, an uptick in the utilization of biologics and immunoglobulins, the broadening of personalized treatment strategies, and intensified research into autoimmune disease mechanisms. Significant trends observed in the same forecast period encompass the increasing application of immunosuppressive therapies, a rise in the adoption of monoclonal antibody treatments, a heightened emphasis on accurate differential diagnosis, the expansion of advanced diagnostic imaging techniques, and the implementation of enhanced patient monitoring protocols.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22104&type=smp

Which Core Factors Are Supporting The Expansion Of The Polymyositis Market?

The rising occurrence of autoimmune conditions is anticipated to fuel the expansion of the polymyositis market in the future. These illnesses are characterized by the body’s immune system erroneously targeting its healthy cells, tissues, or organs, resulting in inflammation and harm. The incidence of autoimmune diseases is on the rise because specific genetic variations can trigger an overly active immune response, increasing individuals’ vulnerability to self-inflicted tissue attacks. This predisposition, coupled with environmental elements like infections, stress, and various lifestyle factors, contributes to the growing number of autoimmune cases. Polymyositis provides a deeper comprehension of autoimmune diseases by illustrating the link between immune system malfunctions and muscle inflammation, thereby revealing crucial insights into their mechanisms and potential therapeutic approaches for similar conditions. As an illustration, data from February 2024, provided by Arthritis Australia, an Australia-based charitable not-for-profit organisation advocating for people with arthritis and musculoskeletal conditions, projected that by 2025, around 562,378 Australians will be affected by rheumatoid arthritis (RA), which represents 14% of the total arthritis population. Consequently, the growing frequency of autoimmune diseases is propelling the Polymyositis market.

Which Segment-Based Categories Are Covered In The Polymyositis Market?

The polymyositis market covered in this report is segmented –

1) By Type: Idiopathic Polymyositis, Dermatomyositis, Inclusion Body Myositis, Overlapping Myositis Syndromes

2) By Diagnosis: Physical Examination, Muscle Biopsy, Electromyography (EMG), Blood Tests, Magnetic Resonance Imaging (MRI)

3) By Treatment: Immunosuppressant, Immunoglobulins, Corticosteroids, Alkylating agents, Monoclonal Antibodies

4) By Distribution Channel: Offline, Online

5) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Idiopathic Polymyositis: Immune-Mediated Polymyositis, Virus-Associated Polymyositis

2) By Dermatomyositis: Classic Dermatomyositis, Amyopathic Dermatomyositis, Juvenile Dermatomyositis

3) By Inclusion Body Myositis: Sporadic Inclusion Body Myositis, Hereditary Inclusion Body Myopathy

4) By Overlapping Myositis Syndromes:Polymyositis with Systemic Lupus Erythematosus (SLE), Polymyositis with Rheumatoid Arthritis (RA), Polymyositis with Systemic Sclerosis, Polymyositis with Mixed Connective Tissue Disease (MCTD)

Which Trends Are Affecting The Polymyositis Market Framework?

Leading companies in the polymyalgia rheumatica market are focused on developing advanced drugs, such as interleukin-6 (IL-6) receptor blockers, to offer more precise and effective treatment options. Interleukin-6 (IL-6) receptor blockers are biological medications that suppress IL-6, a key pro-inflammatory cytokine in autoimmune conditions. By inhibiting IL-6, these therapies reduce inflammation and alleviate symptoms, thereby enhancing the quality of life for PMR patients. For example, in February 2023, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, and Sanofi, a France-based healthcare company, announced the Food and Drug Administration (FDA) approved Kevzara (sarilumab) for the management of polymyalgia rheumatica (PMR) in adults who have not responded adequately to corticosteroids or cannot tolerate reducing their dosage. Kevzara, the first and only biologic approved for this condition, operates by impeding IL-6-mediated signaling. This approval was based on a study where 28.3% of patients receiving sarilumab achieved sustained remission at week 52, in contrast to 10.3% of those on placebo. Kevzara is administered via subcutaneous injection once every two weeks and also holds approval for treating moderately to severely active rheumatoid arthritis. Sanofi’s stock (SNY) is presently valued at $54.13 on the NASDAQ.

Who Are The Companies Shaping The Polymyositis Market Landscape?

Major companies operating in the polymyositis market are Pfizer Inc., F Hoffmann La Roche AG, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Merck & Co. Inc., C H Boehringer Sohn AG & Co. KG, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Fresenius SE & Co. KGaA, UCB S.A., Teva Pharmaceuticals USA Inc., Kezar Life Sciences Inc., Argenx SE, Mallinckrodt Pharmaceuticals plc, Mitsubishi Tanabe Pharma Corporation, Sanofi S.A., AbbVie Inc., Eli Lilly and Company, Janssen Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., CSL Behring

Access The Complete Polymyositis Market Report:

https://www.thebusinessresearchcompany.com/report/polymyositis-global-market-report

Which Region Commands The Largest Share Of The Polymyositis Market?

North America was the largest region in the polymyositis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the polymyositis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Polymyositis Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=22104&type=smp

Browse Through More Reports Similar to the Global Polymyositis Market 2026, By The Business Research Company

Fibromyalgia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report

Esophageal Dysphagia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/esophageal-dysphagia-global-market-report

Sciatica Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/sciatica-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795